 |
|
Source of crucial immune cell in the skin discovered
January 30, 2006Identification of precursor cell may lead to tumor immunotherapy as well as new treatment for rare disorder
Mount Sinai School of Medicine researchers have identified the precursors of cells in the skin that are part of the first line of defense against invading pathogens. The study will appear on Nature Immunology's website this week and will be published in a future issue.
A tight network of cells covering the entire body is formed in the skin by a group of cells known as Langerhans cells. These cells ingest antigens present in the skin and transport them to lymph nodes, activating the immune system to protect the body against pathogens.
"Langerhans cells are particularly important to the development of tumor immunotherapy," said Miriam Merad, MD, PhD, Assistant Professor of Gene and Cell Medicine at Mount Sinai and lead author of the study. "Most vaccines being developed for tumors are injected into the skin and rely on these cells to transport the antigen to the lymph nodes to trigger an immune response against the tumor."
Once Langerhans cells transport an antigen, they need to be replaced to maintain the tight network in the skin. Dr. Merad and colleagues at Mount Sinai School of Medicine recently discovered that when skin is inflamed Langerhans cells are replaced by circulating precursor cells. They have now identified what this precursor cell is and identified a protein that is essential to the transformation of these precursor cells into Langerhans cells.
The researchers put fluorescent beads in mice in a group of immune cells known as monocytes. They then followed the cells to observe their fate. They found that a specific type of monocyte know as Gr-1 homes to inflamed skin, proliferates, and then differentiates to form Langerhans cells. They also found that a protein, called colony stimulating factor receptor (Csf-1) is necessary for the transformation of Gr-1 cells into Langerhans cells.
The researchers state that discovery of how Langerhans cells are replaced "should contribute to ongoing efforts to engineer immune responses in vaccine design and tumor immunotherapy and to a better understanding of the immune response against skin pathogens."
"Now that we know which cells are the precursors to Langerhans cells and the importance of Csf-1, we may be able to enhance tumor vaccines by increasing the recruitment of Langerhans cell precursors to the skin," said Dr. Merad.
Additionally, the researchers point out that the new findings hold promise for potential therapeutic for patients with a Langerhans histocytosis, a rare disease effecting approximately 200,000 children annually. In children with this disorder, large numbers of Langerhans cells infiltrate organs and tissues throughout the body. So, targeting the pathway by which these cells are formed could lead to new therapies to help children who now face the possibility of lifelong complications.
"It is known that Csf-1 levels are elevated in patients with Langerhans histocytosis," said Dr. Merad. "Our findings indicated that finding ways to lower Csf-1 levels may produce new therapeutics for these patients."
The Mount Sinai Hospital / Mount Sinai School of Medicine
Once Langerhans cells transport an antigen, they need to be replaced to maintain the tight network in the skin. Dr. Merad and colleagues at Mount Sinai School of Medicine recently discovered that when skin is inflamed Langerhans cells are replaced by circulating precursor cells. They have now identified what this precursor cell is and identified a protein that is essential to the transformation of these precursor cells into Langerhans cells.
The researchers put fluorescent beads in mice in a group of immune cells known as monocytes. They then followed the cells to observe their fate. They found that a specific type of monocyte know as Gr-1 homes to inflamed skin, proliferates, and then differentiates to form Langerhans cells. They also found that a protein, called colony stimulating factor receptor (Csf-1) is necessary for the transformation of Gr-1 cells into Langerhans cells.
The researchers state that discovery of how Langerhans cells are replaced "should contribute to ongoing efforts to engineer immune responses in vaccine design and tumor immunotherapy and to a better understanding of the immune response against skin pathogens."
"Now that we know which cells are the precursors to Langerhans cells and the importance of Csf-1, we may be able to enhance tumor vaccines by increasing the recruitment of Langerhans cell precursors to the skin," said Dr. Merad.
Additionally, the researchers point out that the new findings hold promise for potential therapeutic for patients with a Langerhans histocytosis, a rare disease effecting approximately 200,000 children annually. In children with this disorder, large numbers of Langerhans cells infiltrate organs and tissues throughout the body. So, targeting the pathway by which these cells are formed could lead to new therapies to help children who now face the possibility of lifelong complications.
"It is known that Csf-1 levels are elevated in patients with Langerhans histocytosis," said Dr. Merad. "Our findings indicated that finding ways to lower Csf-1 levels may produce new therapeutics for these patients."
The Mount Sinai Hospital / Mount Sinai School of Medicine
Immunotherapy Current Events and Immunotherapy News RSSImmune system activated in schizophrenia
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.
Hundreds of genes distinguish patients likely to survive advanced melanoma
Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Alzheimer's lesions found in the retina
The eyes may be the windows to the soul, but new research indicates they also may mirror a brain ravaged by Alzheimer's disease.
Elderly immune system needs a boost
Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease.
Oleocanthal may help prevent, treat Alzheimer's
Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.
University Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease
Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.
Mounting a multi-layered attack on fungal infections
Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.
Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
Researchers testing virus-gene therapy combination against melanoma
Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease.
More Immunotherapy Current Events and Immunotherapy News Articles
 |
Cancer Immunotherapy: Immune Suppression and Tumor Growth by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor) There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait... |
 |
Recombinant Antibodies for Immunotherapy by Melvyn Little PhD (Editor) Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, "arming" mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field,... |
 |
Using the Immune System to Treat Cancer |
 |
Allergens and Allergen Immunotherapy, Fourth Edition (Clinical Allergy and Immunology) by Richard F. Lockey (Editor), Dennis K. Ledford (Editor) Modernized and updated, Allergens and Allergen Immunotherapy, Fourth Edition discusses all major areas of allergens and immunotherapies: pollens animal/insect fungi food the manufacture and standardization of allergen vaccines the administration of vaccines the avoidance and treatment of adverse effects Compiling the research of an influential team of investigators and scientists, Allergens and Allergen Immunotherapy is filled with quick reference charts, tables and indexes. Allergists, immunologists, and otolaryngologists will find this new streamlined fourth edition a great practical reference for on-the-go diagnosis, treatment, and management of allergies. NEW TO THE FOURTH EDITION: new focus on the most... |
 |
Carbohydrate-Based Vaccines and Immunotherapies (Wiley Series in Drug Discovery and Development) by Zhongwu Guo (Author), Geert-Jan Boons (Author) The fundamental science and the latest developments in carbohydrate-based vaccines The relatively new field of glycoimmunology has emerged from the marriage of glycobiology and immunology, in recognition of the important role carbohydrates play as antigenic determinants. Carbohydrate-Based Vaccines and Immunotherapies comprehensively reviews the state of this exciting field, offering a single source for both the fundamental science and the latest developments. With contributions by leading experts, this resource covers the design, synthesis, evaluation, and applications of various carbohydrate-based vaccines, including polysaccharides, neoglycoproteins, and neoglycolipids. The text approaches vaccine design from a chemical and molecular focus, staying in line with... |
 |
The Low Dose Immunotherapy Handbook: Recipes and Lifestlye Advice for Patients on LDA and EPD Treatment by Nicolette, M Dumke (Author) The Low Dose Immunotherapy Handbook: Recipes and Lifestyle Tips for Patients on LDA and EPD Treatment gives 80 recipes for patients on low dose immunotherapy treatment for their food allergies. These recipes are for the basic shot time (EPD) diet and the very mixed diet, and include baked goods, main dishes, and side dishes as well as allowable snacks, desserts and treats that make these diets more livable. It also includes organizational information to help you get ready for your shots and sources of special foods and products that low dose immunotherapy patients need. |
 |
Cancer Vaccines and Immunotherapy (Cambridge Cancer Series) by Peter L. Stern (Editor), Peter C. L. Beverley (Editor), Miles Carroll (Editor) Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments. |
 |
Antiviral Agents, Vaccines and Immunotherapies (Infectious Disease and Therapy) by Stephen Tyring (Editor) Unlike any other source on the subject, Antiviral Agents, Vaccines, and Immunotherapies analyzes the benefits and limitations of every available drug, vaccine, and immunotherapy utilized in the prevention and control of viral diseases. This reference provides in-depth reviews of more than 50 drugs and antiviral agents for HIV, human herpesviruses, human papillomaviruses (HPV), influenza, respiratory syncytial virus, hepatitis B, and analyzes their mechanisms of action, dosage, side effects, and drug resistance. The book also provides an overview of the use of immunoglobulins and monoclonal antibodies for antiviral use and supplies extensive references, tables, and figures throughout the text. |
|
PEPTIDE IMMUNOTHERAPY - COLOSTRUM, A PHYSICIAN'S REFERENCE GUIDE by Andrew M., PhD Keech (Author) | |
 |
Immune Regulation and Immunotherapy in Autoimmune Disease by Jingwu Zhang (Editor) This volume will review the most recent advances in the understanding of cellular and molecular mechanisms for immune responses and immune regulation. Chapters in the first portion of this book will discuss the theoretical basis for current immunotherapies for autoimmune diseases. The second portion of the book will provide an updated review on the research behind the clinical trials/immunotherapies (e.g. T-cell vaccination, antibody therapy, etc.) in the areas of autoimmune diseases by the principal investigators of these studies. These chapters will discuss clinical and basic research as well as immunological data in the context of cellular and molecular mechanisms of the therapies. The book will finish with chapters by leaders in the field who will provide expert views on challenges... |
| © 2009 BrightSurf.com |